Figure 8. Visualization binding affinity of each of the three FDA-approved SSAs to the different SSTR subtypes. This figure was retrieved and adapted from Drugs, Herrera-Martinez A. D., Hofland J., Hofland L. J., et al., Targeted systemic treatment of neuroendocrine tumors: current options and future perspectives, 79:21-42. © 2019 (186).